Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Kineret; Czech Republic: Kineret; Denmark: Kineret; Estonia: Kineret; Finland: Kineret; France: Kineret; Germany: Kineret; Greece: Kineret; Hungary: Kineret; Ireland: Kineret; Italy: Kineret; Latvia: Kineret; Lithuania: Kineret; Luxembourg: Kineret; Malta: Kineret; Netherlands: Kineret; Poland: Kineret; Portugal: Kineret; Romania: Kineret; Slovakia: Kineret; Slovenia: Kineret; Spain: Kineret; Sweden: Kineret; UK: Kineret.

North America

Canada: Kineret; USA: Kineret.

Drug combinations


Anakinra: C~759~H~1186~N~208~O~232~S~10~. Mw: 17258.01. (1) Interleukin 1 receptor antagonist (human isoform x reduced), N^2^-L-methionyl-; (2) N^2^-L-Methionylinterleukin 1 receptor antagonist (human isoform x reduced). CAS-143090-92-0 (1994).

Pharmacologic Category

Biologic Response Modifiers. Disease-modifying Antirheumatic Drugs. Interleukin 1 Receptor Antagonist. (ATC-Code: L04AC03).

Mechanism of action

Antagonist of the interleukin-1 (IL~1~) receptor.

Therapeutic use

Treatment of rheumatoid arthritis in adults.

Pregnancy and lactiation implications

There are no controlled trials in pregnant women. Use with caution during lactation.

Unlabeled use


Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation. Active infections (chronic or local).

Warnings and precautions

May cause hypersensitivity, anaphylaxis, or anaphylactoid reactions. Caution should be exercised when used in history of new/recurrent infections, with conditions that predispose to infections, or with chronic, latent, or localized infections (if a serious infection develops, therapy should be discontinued). Use may affect defenses against malignancies. Use with caution in asthma (risk of serious infection), in hematologic abnormalities (decreases in hematologic parameters), or in renal impairment. If possible, should not be used in combination with tumor necrosis factor antagonists. Use caution in the elderly. Use is not recommended in children. Live vaccines should not be given concurrently. The packaging (needle cover) contains latex.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart